Axsome Therapeutics, Inc (AXSM)
Health Care ยท Pharmaceutical Preparations
Axsome Therapeutics, Inc (AXSM) is listed on Nasdaq, where its shares have traded since November 19, 2015. SentiSense covers Axsome Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Herriot Tabuteau is its chief executive officer. The company reports 925 employees, and its corporate website is www.axsome.com.
About Axsome Therapeutics, Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Latest reported results
Axsome Therapeutics Inc. reported revenue of $259.7 million for Q3 FY2026, up 51.9% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 494 institutions reported holding AXSM, with 38.1 million shares worth $9.3 billion in aggregate. The largest reported holders were Vanguard, BlackRock and Invesco Ltd. Of the 5 largest reported holders, 1 added shares and 4 reduced their positions during the quarter.
More on AXSM
- AXSM sentiment: whether news and social coverage of Axsome Therapeutics, Inc leans bullish or bearish, and the stories driving it.
- AXSM ownership: all 494 reporting institutions, plus insider and congressional trades.
- AXSM financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Axsome Therapeutics, Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Axsome Therapeutics, Inc do?
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options.
What sector is AXSM in?
SentiSense classifies Axsome Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does AXSM stock trade?
Axsome Therapeutics, Inc (AXSM) is listed on Nasdaq, where its shares have traded since November 19, 2015.
Who is the CEO of Axsome Therapeutics, Inc?
Herriot Tabuteau is the chief executive officer of Axsome Therapeutics, Inc.